Bio-Techne Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.2B-0.4% YoYTTM through 31 Mar 2026
Net Income $109.6M-34.8% YoYTTM through 31 Mar 2026
Free Cash Flow $263.2MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 64.8% |
| EBITDA Margin | 28.7% |
| Operating Margin | 8.4% |
| Net Margin | 9.0% |
Returns
3.8%ROE
2.9%ROA
5.4%ROIC
Balance Sheet Health
Debt / Equity0.18x
Current Ratio4.55x
Net Debt$201M
Cash & Equivalents$264.7M
Quality Metrics
Altman Z-Score16.35
Piotroski F-Score6 / 9
FCF Margin21.7%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2026: $1.2B
Diluted EPS$1.16TTMFY2026: $1.16
Dividend
$0.16Per share, FY20260.59%Yield-12.9%5-yr growth
Capital Allocation
Capex Intensity2.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Protein Sciences | $870.2M | +5.0% | View detailsPositioned to benefit from long-term biopharma demand and recovery in China, supported by AI-enhanced designer proteins. |
| Diagnostics and Spatial Biology | $346.3M | +6.0% | View detailsExpected to see margin expansion following the divestiture of the lower-margin Exosome Diagnostics business in early FY2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.